Jazz Pharmaceuticals plc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
52.9%projected annual EPS growth
Analyst Coverage
20analysts covering
FY Revenue (est.)
$4.7Bnext fiscal year
FY EPS (est.)
$25.05next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 9 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Xywav Net Product Sales Quarterly408M
Epidiolex Net Product Sales Quarterly250M
Oncology Segment Net Product Sales Quarterly333.4M
Watch Items
- FDA PDUFA Action Date for Zanidatamab (Ziihera) in first-line HER2-positive gastroesophageal adenocarcinoma (GEA)Trigger: August 25, 2026Action: Monitor FDA decision and prepare for commercial launch execution in H2 2026.
- Zepzelca Phase 3 LAGOON Trial in Second-Line Small Cell Lung CancerTrigger: Clinical trial data updates and overall survival readoutsAction: Assess clinical efficacy and potential impact on future regulatory submissions.
Research as of 2 Sep 2026